Clinical Pharmacokinetics and Pharmacodynamics of CSL112 (vol 62, pg 541, 2023)

被引：0
|
作者：
Ortega-Paz, Luis [1 ]
Giordano, Salvatore [1 ,2 ]
Capodanno, Davide [3 ]
Mehran, Roxana [4 ]
Gibson, C. Michael [5 ]
Angiolillo, Dominick J. [1 ]
机构：
[1] Univ Florida, Div Cardiol, Coll Med, 655 West 8th St, Jacksonville, FL 32209 USA
[2] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Div Cardiol, Catanzaro, Italy
[3] Univ Catania, Div Cardiol, AOU Policlin Vittorio Emanuele, Catania, Italy
[4] Icahn Sch Med Mt Sinai, Zena & Michael A Wiener Cardiovasc Inst, New York, NY USA
[5] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Cardiovasc Div, Boston, MA USA
来源：
CLINICAL PHARMACOKINETICS | 2023年 / 62卷 / 07期
关键词：
D O I：
10.1007/s40262-023-01277-9
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1043 / 1043
页数：1
相关论文
共 50 条
  • [1] Clinical Pharmacokinetics and Pharmacodynamics of CSL112
    Ortega-Paz, Luis
    Giordano, Salvatore
    Capodanno, Davide
    Mehran, Roxana
    Gibson, C. Michael
    Angiolillo, Dominick J. J.
    CLINICAL PHARMACOKINETICS, 2023, 62 (04) : 541 - 558
  • [2] Clinical Pharmacokinetics and Pharmacodynamics of CSL112
    Luis Ortega-Paz
    Salvatore Giordano
    Davide Capodanno
    Roxana Mehran
    C. Michael Gibson
    Dominick J. Angiolillo
    Clinical Pharmacokinetics, 2023, 62 : 541 - 558
  • [3] Correction to: Clinical Pharmacokinetics and Pharmacodynamics of CSL112
    Luis Ortega-Paz
    Salvatore Giordano
    Davide Capodanno
    Roxana Mehran
    C. Michael Gibson
    Dominick J. Angiolillo
    Clinical Pharmacokinetics, 2023, 62 : 1043 - 1043
  • [4] Pharmacokinetics and Safety of CSL112 (Apolipoprotein A-I [Human]) in Adults With Moderate Renal Impairment and Normal Renal Function
    Tortorici, Michael A.
    Duffy, Danielle
    Evans, Rebecca
    Feaster, John
    Gille, Andreas
    Mant, Timothy G. K.
    Wright, Samuel D.
    D'Andrea, Denise
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (05): : 628 - 636
  • [5] Antiatherosclerotic Effects of CSL112 Mediated by Enhanced Cholesterol Efflux Capacity (vol 11, e024754, 2022)
    Kingwell, A.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2023, 12 (05):
  • [6] PHARMACOKINETICS AND SAFETY OF A NOVEL APOLIPOPROTEIN A-I THERAPY, CSL112, IN ADULTS WITH MODERATE RENAL IMPAIRMENT (RI) AND NORMAL RENAL FUNCTION
    Tortorici, M. A.
    Duffy, D.
    Zhou, M.
    Evans, R.
    Feaster, J.
    D'Andrea, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S90 - S90
  • [7] Measles (vol 62, pg 29,2023)
    Malbos, Damien
    ACTUALITES PHARMACEUTIQUES, 2023, 62 (629): : 11 - 11
  • [8] Imaginary Universe (vol 328, pg 62, 2023)
    Renou, Marc-Olivier
    SCIENTIFIC AMERICAN, 2023, 328 (06) : 7 - 7
  • [9] PHARMACODYNAMICS, PHARMACOKINETICS, AND CLINICAL USES OF FENTANYL, SUFENTANIL, AND ALFENTANIL (VOL 22, PG 239, 1993)
    WILLENS, JS
    MYSLINSKI, NR
    HEART & LUNG, 1993, 22 (04): : 307 - 307
  • [10] RETRACTED: Pharmacokinetics and clinical pharmacodynamics of the new propofol prodrug GPI 15715 in volunteers (Retracted article. See vol. 112, pg. 1058, 2010)
    Fechner, J
    Ihmsen, H
    Hatterscheid, D
    Schiessl, C
    Vornov, JJ
    Burak, E
    Schwilden, H
    Schüttler, JR
    ANESTHESIOLOGY, 2003, 99 (02) : 303 - 313
12345